Form 8-K InMed Pharmaceuticals For: Mar 04

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 4, 2021

 

 

INMED PHARMACEUTICALS INC.

(Exact Name of Company as Specified in Charter)

 

 

British Columbia		001-39685		98-1428279
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

InMed Pharmaceuticals Inc.
Suite 310 - 815 W. Hastings Street,
Vancouver, B.C.
Canada		V6C 1B4
(Address of Principal Executive Offices)		(Zip Code)

 

Company’s telephone number, including area code: (604) 669-7207

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares, no par value		INM		The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company  ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On March 3, 2021, the Company issued a press release announcing its participation in two virtual investor conferences in March 2021. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

 

The information set forth in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d)

Exhibits:

 

The following exhibits shall be deemed to be furnished, and not filed:

 

Exhibit No.		Description
99.1		News release, dated March 3, 2021

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	INMED PHARMACEUTICALS INC.
Date: March 4, 2021	By:	/s/ Bruce Colwill
		Bruce Colwill
		Chief Financial Officer

 

 

2

 

Exhibit 99.1

 

TSX:IN NASDAQ: INM   Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com

 

InMed to Present at Virtual Conferences in March 2021

 

Vancouver, BC – March 3^rd, 2021 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX: IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates targeting diseases with high unmet medical need and leading the clinical development of cannabinol (“CBN”), today announced that Eric A. Adams, President and CEO of InMed, will be presenting at investor conferences in March 2021. The details of each conference are included below.

 

H.C. Wainwright Global Life Sciences Conference

Date: March 9-10^th

Presentation Details: The company presentation will be available on demand beginning March 9^th at 7am EST, and can be found at the below link. The presentation will be archived for 90 days following the conclusion of the event.

Presentation Link: https://journey.ct.events/view/d9d5aa94-1651-4380-9c75-b8bf018118e6

 

33^rd Annual ROTH Conference

Date: March 15-17^th

Presentation Details: Company CEO Eric A. Adams will participate in a Fireside Chat with ROTH analyst Scott Henry, CFA.

Fireside Chat Date/Time: Monday, March 15^th at 4:30pm EST

Fireside Chat Link: https://wsw.com/webcast/roth35/inm/1678644

 

For 1x1s meetings with Management, conference participants can send a request to [email protected]. Information on each event, as well as links to presentations as they become available, will be posted on InMed’s event page, which can be found at: www.inmedpharma.com/about/events.

 

About InMed: InMed Pharmaceuticals is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (“CBN”), in diseases with high unmet medical need. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com.

 

Investor Contact: Edison Group
Joe Green/Laine Yonker
T:  +1.646.653.7030/+1.646.653.7035
E:  [email protected]
[email protected]

 

 

Cautionary Note Regarding Forward-Looking Information:

 

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: presenting at conferences in March 2021, including the H.C. Wainwright Global Life Sciences Conference and the 33rd Annual ROTH Conference; leading the way in the clinical development of cannabinol (CBN); developing a pipeline of cannabinoid-based pharmaceutical drug candidates in diseases with high unmet medical need; and delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs.

 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

 

NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

 

 

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Globe Life Inc. Investors to Inquire About Securities Class Action Investigation – GL
• AirBoss Announces Details for AGSM and Q1 2024 Results Timing
• Robbins LLP Reminds IRobot Corporation Shareholders of the Pending May 7, 2024 Lead Plaintiff Deadline